Pharma major Lupin on Thursday announced the launch of the authorized generic for Horizon Therapeutics Plc's Vimovo (naproxen/esomeprazole magnesium) delayed-release tablets, 375 mg/20 mg and 500 mg/20 mg in the US.
The product is a combination of naproxen, a non-steroidal anti-inflammatory drug (NSAID), and esomeprazole magnesium, a proton pump inhibitor (PPI) indicated in adult and adolescent patients 12 years of age and older weighing at least 38 kg, requiring naproxen for symptomatic relief of arthritis and esomeprazole magnesium to decrease the risk of developing naproxen-associated gastric ulcers.
Naproxen and Esomeprazole Magnesium delayed-release tablets had an annual sales of approximately $400 million in the US. (IQVIA MAT January 2020).
On a consolidated basis, Lupin reported a net loss of Rs 835 crore in Q3 December 2019 as against a net loss of Rs 151.75 crore in Q3 December 2018. Net sales declined 2.8% to Rs 3,716.09 crore in Q3 December 2019 over Q3 December 2018.
Lupin is engaged in producing, developing and marketing a range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) across the world. The firm offers products in the cardiovascular, diabetology, asthma, pediatrics, central nervous system, gastro-intestinal, anti-infectives and non-steroidal anti-inflammatory drug therapy areas.
Shares of Lupin fell 1.39% to Rs 667. The scrip traded in the range of Rs 657.80 to Rs 670.90 so far.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
